Ovarian function in female survivors after multimodal Ewing sarcoma therapy

摘要: Background With advances in cancer care, more young women with Ewing sarcoma (ES) survive after treatment. Thus, we sought to analyze the ovarian function prepubertal, pubertal and postpubertal females receiving multimodal therapy for ES, identify patients at risk of infertility on whom fertility preservation would be indicated. Procedures Twenty-seven female survivors ES were included this retrospective multiinstitutional study. Patients classified into four groups according treatment received: chemotherapy (CHT) without pelvic radiation (pRT), pRT, CHT autologous hematopoietic cell stem rescue (aHSCT) CHT + pRT + aHSCT. The outcomes analyzed. Results At a median follow-up 5.7 years from diagnosis, age 16.3 years, 67% had premature insufficiency, including all RT 87.5% who underwent aHSCT, independent chemoprotection. Thirty-seven percent clinical syndrome menopause. relative (RR) insufficiency survivor was 3.9 (p 0.03) 2.4 0.07) aHSCT. On multivariate analysis, significant predictor higher over alone. Conclusions A large proportion develop insufficiency. guardians should informed about reproductive potential strategies considered individually. Pediatr Blood Cancer 2015;62:341–345. © 2014 Wiley Periodicals, Inc.